Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus. / Magkos, Faidon; Nikonova, Elena; Fain, Randi; Zhou, Sharon; Ma, Tony; Shanahan, William.
In: Obesity, Vol. 25, No. 5, 2017, p. 842-849.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus
AU - Magkos, Faidon
AU - Nikonova, Elena
AU - Fain, Randi
AU - Zhou, Sharon
AU - Ma, Tony
AU - Shanahan, William
N1 - © 2017 The Obesity Society.
PY - 2017
Y1 - 2017
N2 - Objective: Lorcaserin, a 5-HT2C receptor agonist approved for chronic weight management, is also associated with improvements in glycemic parameters in patients with/without type 2 diabetes mellitus (T2DM), but the extent to which these effects are mediated by weight loss is unknown. This post hoc analysis further examines glycemic data from the Phase III BLOOM-DM study stratified by weight changes.Methods: Patients with T2DM were randomized to lorcaserin 10 mg twice daily or placebo. Glycemic parameters were reported by Week (W) 12 weight loss status ≥5% (Group ≥5%) or <5% (Group <5%). Glycemic parameter changes were analyzed using ANCOVA; the relationship between glycemic parameter changes and percent weight loss was assessed by simple regression modeling.Results: Group ≥5% receiving lorcaserin had greater improvements in fasting plasma glucose (FPG) at W2 (prior to significant weight loss) and greater improvements in glycated hemoglobin (HbA1c) at W12 versus placebo. These improvements were maintained through W52 (FPG, -29.3 mg/dL vs. -24.2 mg/dL; HbA1c, -1.2% vs. -1.1%). Group <5% treated with lorcaserin also had larger decreases in FPG (-28.3 mg/dL vs. -10.0 mg/dL) and HbA1c (-0.8% vs. -0.4%) at W52 versus placebo despite limited weight loss.Conclusions: Lorcaserin may have beneficial effects on glycemic control with or without weight loss.
AB - Objective: Lorcaserin, a 5-HT2C receptor agonist approved for chronic weight management, is also associated with improvements in glycemic parameters in patients with/without type 2 diabetes mellitus (T2DM), but the extent to which these effects are mediated by weight loss is unknown. This post hoc analysis further examines glycemic data from the Phase III BLOOM-DM study stratified by weight changes.Methods: Patients with T2DM were randomized to lorcaserin 10 mg twice daily or placebo. Glycemic parameters were reported by Week (W) 12 weight loss status ≥5% (Group ≥5%) or <5% (Group <5%). Glycemic parameter changes were analyzed using ANCOVA; the relationship between glycemic parameter changes and percent weight loss was assessed by simple regression modeling.Results: Group ≥5% receiving lorcaserin had greater improvements in fasting plasma glucose (FPG) at W2 (prior to significant weight loss) and greater improvements in glycated hemoglobin (HbA1c) at W12 versus placebo. These improvements were maintained through W52 (FPG, -29.3 mg/dL vs. -24.2 mg/dL; HbA1c, -1.2% vs. -1.1%). Group <5% treated with lorcaserin also had larger decreases in FPG (-28.3 mg/dL vs. -10.0 mg/dL) and HbA1c (-0.8% vs. -0.4%) at W52 versus placebo despite limited weight loss.Conclusions: Lorcaserin may have beneficial effects on glycemic control with or without weight loss.
KW - Adolescent
KW - Adult
KW - Aged
KW - Benzazepines/administration & dosage
KW - Blood Glucose/drug effects
KW - Diabetes Mellitus, Type 2/blood
KW - Double-Blind Method
KW - Female
KW - Glycated Hemoglobin A/analysis
KW - Humans
KW - Male
KW - Middle Aged
KW - Retrospective Studies
KW - Young Adult
U2 - 10.1002/oby.21798
DO - 10.1002/oby.21798
M3 - Journal article
C2 - 28345809
VL - 25
SP - 842
EP - 849
JO - Obesity
JF - Obesity
SN - 1930-7381
IS - 5
ER -
ID: 210874540